| Outcome Measures: |
Primary: Number of Participants Who Experienced an Adverse Event During the Study, 39 days | Secondary: Number of Participants Who Experienced an Adverse Event - Titration Scheme 1, In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis in 10-mg q.a.c. increments on Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1 of the study., 25 days|Number of Participants Who Experienced an Adverse Event - Titration Scheme 2, Titration Scheme #2 (Titration Phase, Days 1 to 4) was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration., 25 days|24-Hour Weighted Mean Blood Glucose Levels (mg/dL) by Treatment Group on Day 7, Measurement of the 24-hour weighted mean blood glucose levels of participants receiving MK-0941 or placebo while on basal insulin on Day 7., 24 hours|Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period, During the Outpatient Treatment Period, participants were followed for an additional 2 weeks while at home., Outpatient Days 1 to 14
|
